Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese Subjects

Next Previous
Search
Trial Profile

A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Acute heart failure; Chronic heart failure; Heart failure
  • Focus Pharmacokinetics
  • Sponsors Cytokinetics

    • Most Recent Events

    • 20 Aug 2021 Results of two clinical studies evaluating pharmacokinetics, tolerability, and safety of single and multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian subjects published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 27 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top